PF-07209960

PF-07209960 is an investigational, first-in-class bispecific fusion protein developed for cancer immunotherapy. It consists of a bivalent high-affinity anti-programmed cell death protein 1 (PD-1) full-length IgG antibody fused to a single potency-reduced interleukin-15 (IL-15) mutein. The drug is designed to simultaneously block the PD-1 immune checkpoint and activate T cells and natural killer (NK) cells via the IL-15 pathway, thereby enhancing antitumor immune responses. PF-07209960 was administered subcutaneously in clinical trials for patients with advanced or metastatic solid tumors who had limited treatment options or were resistant to prior anti-PD-(L)1 therapies. The mechanism aims to achieve greater antitumor activity than either anti-PD-(L)1 or IL-15 agonists alone[1][4][7].

Other names

PD-1-targeted IL-15 mutein fusion proteinPD1-targeted IL-15 mutein fusion proteinPD 1-targeted IL-15 mutein fusion protein